CERCHIA, CARMEN
 Distribuzione geografica
Continente #
AS - Asia 2.111
NA - Nord America 1.794
EU - Europa 1.464
SA - Sud America 224
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
Totale 5.661
Nazione #
US - Stati Uniti d'America 1.731
SG - Singapore 997
RU - Federazione Russa 632
CN - Cina 452
IT - Italia 446
VN - Vietnam 299
BR - Brasile 166
HK - Hong Kong 136
DE - Germania 70
FR - Francia 69
FI - Finlandia 48
GB - Regno Unito 45
NL - Olanda 44
JP - Giappone 37
IE - Irlanda 35
KR - Corea 35
IN - India 34
CA - Canada 31
CI - Costa d'Avorio 27
MX - Messico 21
IQ - Iraq 20
SE - Svezia 16
ZA - Sudafrica 16
AR - Argentina 15
BD - Bangladesh 13
ID - Indonesia 12
AT - Austria 11
TR - Turchia 10
VE - Venezuela 10
PH - Filippine 9
PK - Pakistan 9
CL - Cile 8
EC - Ecuador 8
ES - Italia 8
TH - Thailandia 8
TW - Taiwan 8
PL - Polonia 7
PY - Paraguay 6
JO - Giordania 5
UA - Ucraina 5
BE - Belgio 4
CO - Colombia 4
KH - Cambogia 4
LT - Lituania 4
NP - Nepal 4
RO - Romania 4
CY - Cipro 3
EG - Egitto 3
MA - Marocco 3
PE - Perù 3
RS - Serbia 3
SA - Arabia Saudita 3
TN - Tunisia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BO - Bolivia 2
BS - Bahamas 2
BY - Bielorussia 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
JM - Giamaica 2
LV - Lettonia 2
MD - Moldavia 2
UG - Uganda 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AW - Aruba 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
CU - Cuba 1
DM - Dominica 1
DZ - Algeria 1
GE - Georgia 1
GM - Gambi 1
GP - Guadalupe 1
GR - Grecia 1
HR - Croazia 1
IR - Iran 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LS - Lesotho 1
LY - Libia 1
MN - Mongolia 1
MW - Malawi 1
MY - Malesia 1
NE - Niger 1
NG - Nigeria 1
NI - Nicaragua 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TT - Trinidad e Tobago 1
TZ - Tanzania 1
Totale 5.661
Città #
Singapore 504
San Jose 386
Ashburn 187
Moscow 146
Hefei 143
Naples 134
Dallas 131
Hong Kong 131
Beijing 107
Chandler 93
Ho Chi Minh City 85
Santa Clara 73
Hanoi 70
Napoli 45
Lauterbourg 43
Millbury 43
Los Angeles 37
Amsterdam 35
Tokyo 33
The Dalles 31
Des Moines 29
Seoul 27
Milan 26
New York 24
Buffalo 22
Princeton 20
Redondo Beach 20
São Paulo 20
Council Bluffs 19
Boston 18
Rome 18
Helsinki 17
Frankfurt am Main 16
Lawrence 16
Nanjing 16
Salerno 16
Munich 14
Orem 14
Brooklyn 13
Haiphong 12
Mexico City 12
Nuremberg 12
Wilmington 12
Montreal 11
Atlanta 10
London 10
Baghdad 9
Johannesburg 9
Stockholm 9
Chicago 8
Vienna 8
Can Tho 7
Da Nang 7
Falkenstein 7
Guangzhou 7
Ottawa 7
Phoenix 7
Seattle 7
Biên Hòa 6
Hebei 6
Shenyang 6
Toronto 6
Turku 6
Belo Horizonte 5
Casoria 5
Dublin 5
Falls Church 5
Goiânia 5
Hải Dương 5
Kochi 5
Lappeenranta 5
Manchester 5
Shanghai 5
Avellino 4
Bangkok 4
Bologna 4
Brussels 4
Buccino 4
Bắc Ninh 4
Changsha 4
Charlotte 4
Cologne 4
Dong Ket 4
Enfield 4
Fairfield 4
Fisciano 4
Guayaquil 4
Houston 4
Mumbai 4
Nanchang 4
Palermo 4
Philadelphia 4
Phnom Penh 4
Portland 4
Pune 4
Qingdao 4
Querétaro 4
Quảng Ngãi 4
Redwood City 4
San Francisco 4
Totale 3.181
Nome #
Unlocking the Potential of Generative Artificial Intelligence in Drug Discovery 176
Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination 174
Cdc25 inhibitors in melanoma cells 156
Novel Non-Peptide Small Molecules Preventing IKKβ/NEMO Association Inhibit NF-κB Activation in LPS-Stimulated J774 Macrophages 155
App maturation and intracellular localization are controlled by a specific inhibitor of 37/67 kda laminin-1 receptor in neuronal cells 141
Discovery of a Novel Small Molecule Inhibitor Targeting the Frataxin/Ubiquitin Interaction via Structure-Based Virtual Screening and Bioassays 140
Discovery Of Novel Peroxisome Proliferator-Activated Receptor γ (PPARγ) Scaffolds With Partial Agonist Binding Properties By Integrated In Silico/In Vitro Work Flow 139
Ligand-based chemoinformatic discovery of a novel small molecule inhibitor targeting CDC25 dual specificity phosphatases and displaying in vitro efficacy against melanoma cells 138
A compound-based proteomic approach discloses 15-ketoatractyligenin methyl ester as a new PPARγ partial agonist with anti-proliferative ability 135
Discovery of Novel Naphthylphenylketone and Naphthylphenylamine Derivatives as Cell Division Cycle 25B (CDC25B) Phosphatase Inhibitors: Design, Synthesis, Inhibition Mechanism, and in Vitro Efficacy against Melanoma Cell Lines 135
Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme 131
SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells 129
In Silico Identification of Novel Inhibitors Targeting the Homodimeric Interface of Superoxide Dismutase from the Dental Pathogen Streptococcus mutans 120
The antiproliferative and proapoptotic effects of cladosporols A and B are related to their different binding mode as PPARγ ligands 117
Characterization of novel inhibitors of CDC25 phosphatases: biochemical and biological analysis 117
Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents 115
Identification of selective 5-LOX and FLAP inhibitors as novel anti-inflammatory agents by ligand-based virtual screening 114
Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new L-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors 113
Identification of a new series of amides as non-covalent proteasome inhibitors 109
Small Molecule Drugs And Targeted Therapy For Melanoma: Current Strategies And Future Directions 108
Methyl-Transferase-Like Protein 16 (METTL16): The Intriguing Journey of a Key Epitranscriptomic Player Becoming an Emerging Biological Target 106
Easy access to α-ketoamides as SARS-CoV-2 and MERS Mpro inhibitors via the PADAM oxidation route 105
Synthesis and in vitro cytotoxicity of benzoxazole‐based PPARα/γ antagonists in colorectal cancer cell lines 104
Sulfonimide and amide derivatives as novel PPARα antagonists: Synthesis, antiproliferative activity, and docking studies 104
Development of novel amides as noncovalent inhibitors of immunoproteasomes 102
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities 102
Deep generative models in the quest for anticancer drugs: ways forward 101
New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity 101
Exploring structural relationships between bioactive and commercial chemical space and developing target hypotheses for compound acquisition 99
Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists 98
Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature 97
A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties 95
Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein 93
In silico methods to address polypharmacology: Current status, applications and future perspectives 90
Selective PPARγ modulators for Type 2 diabetes treatment: How far have we come and what does the future hold? 90
“DompeKeys”: a set of novel substructure-based descriptors for efficient chemical space mapping, development and structural interpretation of machine learning models, and indexing of large databases 88
Impairment of Nucleolin Activity and Phosphorylation by a Trachylobane Diterpene from Psiadia punctulata in Cancer Cells 88
Enhancing De Novo Drug Design across Multiple Therapeutic Targets with CVAE Generative Models 87
Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors 86
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome 86
Exploring the Role of N(6)-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice 85
New avenues in artificial-intelligence-assisted drug discovery 80
Computational studies of SARS-CoV-2 3clpro: Insights from md simulations 78
“Molecular Anatomy”: a new multi-dimensional hierarchical scaffold analysis tool 75
A New Antidiabetic Agent Showing Short- and Long-Term Effects Due to Peroxisome Proliferator-Activated Receptor Alpha/Gamma Dual Agonism and Mitochondrial Pyruvate Carrier Inhibition 73
In Silico Drug Design and Discovery: Big Data for Small Molecule Design 68
Binding mode exploration of b1 receptor antagonists’ by the use of molecular dynamics and docking simulation—how different target engagement can determine different biological effects 68
Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode 67
A Series of Ferulic Acid Amides Reveals Unexpected Peroxiredoxin 1 Inhibitory Activity with in vivo Antidiabetic and Hypolipidemic Effects 66
A sulfonimide derivative of bezafibrate as a dual inhibitor of cyclooxygenase-2 and PPARα 63
A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity 63
Challenging triple negative breast cancer through HDAC6 selective inhibition: Novel cap-group identification, structure-activity relationships, computational and biological studies 60
Identification of the First PPARα/γ Dual Agonist Able to Bind to Canonical and Alternate Sites of PPARγ and to Inhibit its Cdk5-Mediated Phosphorylation 59
Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy 58
Editorial: Recent trends in anti-cancer drug discovery by in silico methods 55
Evaluation of molecular mechanisms of (Z)-3-(pentadec-10′-enyl)-catechol (litreol) and synthetic derivatives as inhibitors of human leukotriene biosynthesis 32
null 26
Structural and functional characterization of chemically modified antisense oligonucleotides targeting miR-214-3p in endothelial cells 23
Artificial intelligence in the development of small nucleic acid therapeutics: toward smarter and safer medicines 21
Artificial Intelligence in De Novo Drug Design 18
Fine-tuning the combination of novel spirocyclic capping moieties and heterocyclic zinc binding groups for selective HDAC6 inhibition: design, synthesis, kinetic and biological studies 17
AI-Driven Discovery of microRNA Targets for Disease Therapy and Drug Development 16
ProfhEX: Empowering Early Drug Discovery with Machine Learning-Based Target Profiling and Liability Prediction 16
Artificial Intelligence in Structure-Based Drug Design 13
Artificial Intelligence in Ligand-Based Drug Design 12
In Silico Drug Design and Discovery: Big Data for Small Molecule Design—2nd Edition 3
Totale 5.799
Categoria #
all - tutte 17.626
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.626


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218 0 0 0 0 0 0 0 0 0 0 0 8
2021/2022257 2 3 6 8 18 11 1 4 53 3 51 97
2022/2023285 36 15 17 23 15 30 7 27 40 33 22 20
2023/2024282 18 23 27 22 6 19 8 70 3 4 61 21
2024/20251.533 65 85 14 24 51 93 199 112 62 120 562 146
2025/20263.089 295 241 401 270 462 146 365 177 371 219 102 40
Totale 5.799